{"product_id":"tesamorelin","title":"Tesamorelin","description":"\u003cdiv class=\"strapi-description text-sm text-[#4B5563] md:text-base line-clamp-6\"\u003e\n\u003cp\u003eTesamorelin research compound. Supplied as a lyophilized peptide reference material for laboratory research applications.\u003c\/p\u003e\n\u003cp\u003eThis product is purity-tested for compound identity and is intended for in vitro experimentation, analytical reference, or scientific characterization studies.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFor laboratory research use only. Not for human or veterinary use.\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/div\u003e\u003cdiv class=\"container px-3\"\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"Characteristics\" id=\"characteristics\"\u003eCharacteristics\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eMolecular Formula\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003eC221H366N72O67S\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eCAS\tNumber\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003e218949-48-5\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eMolar Mass\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003e5135.9 g\/mol\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eAmino Acid Sequence\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003eTyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eSynonyms\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003e TH9507, Egrifta, Lipodystrophy Drug\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eSolubility\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003eWater-soluble\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eOrganoleptic Profile\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003eWhite to off-white powder\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eComposition\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003eLyophilized powder - requires reconstitution\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"How does Tesamorelin work?\" id=\"how-does-tesamorelin-work\"\u003eHow does Tesamorelin work?\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\u003cp\u003eTesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog that has been the subject of extensive research in the field of endocrinology and metabolism. This peptide's primary mechanism of action involves binding to and activating the growth hormone-releasing hormone receptor (GHRHR) in the anterior pituitary gland. This activation stimulates the synthesis and pulsatile release of endogenous growth hormone (GH), which in turn promotes the production of insulin-like growth factor-1 (IGF-1) in the liver and other tissues.\u003c\/p\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"Research\" id=\"research\"\u003eResearch\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\u003cul\u003e\n\u003cli\u003e\u003cp\u003eVisceral Adipose Tissue (VAT) Reduction: Clinical studies have shown that tesamorelin can significantly reduce VAT in individuals with HIV-associated lipodystrophy and in obese individuals without HIV. This reduction in VAT has been associated with improvements in metabolic health markers.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eInsulin Sensitivity: Investigations have indicated that tesamorelin treatment may improve insulin sensitivity in certain populations, including individuals with HIV-associated lipodystrophy and obese individuals without HIV.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eCognitive Function: Some studies have explored tesamorelin's potential effects on cognitive function in older adults with mild cognitive impairment (MCI). Preliminary findings suggest possible improvements in executive function, attention, and memory.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eMuscle Mass and Strength: Research has indicated that tesamorelin may increase muscle mass and strength in older adults and individuals with HIV-associated lipodystrophy.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eBone Health: Studies have observed increases in bone mineral density (BMD) in individuals with HIV-associated lipodystrophy following tesamorelin treatment.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"Side Effects\" id=\"side-effects\"\u003eSide Effects\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cp\u003eInjection site reactions\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eEdema\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eArthralgia\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eHypersensitivity reactions\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eLess frequent side effects may include headache, dizziness, and gastrointestinal disturbances. In rare cases, tesamorelin may cause carpal tunnel syndrome or increase the risk of malignancy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"Summary\" id=\"summary\"\u003eSummary\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\u003cp\u003eTesamorelin is a potent growth hormone-releasing hormone (GHRH) analog that has been extensively researched for its potential to improve metabolic health, reduce visceral adipose tissue (VAT), and enhance cognitive function in various populations. By stimulating the production and release of endogenous growth hormone (GH) from the anterior pituitary gland, tesamorelin promotes the production of insulin-like growth factor-1 (IGF-1), leading to numerous metabolic and cognitive benefits. Studies have demonstrated that tesamorelin significantly reduces VAT, improves insulin sensitivity, enhances cognitive function, increases muscle mass and strength, and promotes bone health in individuals with HIV-associated lipodystrophy, obesity, and age-related cognitive decline. As a research peptide, tesamorelin holds promise for further investigating the complex interplay between growth hormone, metabolism, and cognitive function, potentially leading to the development of novel therapeutic strategies for various metabolic and cognitive disorders.\u003c\/p\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"References\" id=\"references\"\u003eReferences\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\n\u003col\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31644039\/\"\u003eLiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/21668043\/\"\u003eDhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32701508\/\"\u003eFourman LT, Billingsley JM, Agyapong G, Ho Sui SJ, Feldpausch MN, Purdy J, Zheng I, Pan CS, Corey KE, Torriani M, Kleiner DE, Hadigan CM, Stanley TL, Chung RT, Grinspoon SK. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight. 2020.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/22298602\/\"\u003eSpooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30920787\/\"\u003eClinical Review Report: Tesamorelin (Egrifta) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33756511\/\"\u003eLake JE, La K, Erlandson KM, Adrian S, Yenokyan G, Scherzinger A, Dubé MP, Stanley T, Grinspoon S, Falutz J, Mamputu JC, Marsolais C, McComsey GA, Brown TT. Tesamorelin improves fat quality independent of changes in fat quantity. AIDS. 2021.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30896905\/\"\u003ePharmacoeconomic Review Report: Tesamorelin (Egrifta) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/21283099\/\"\u003eGrunfeld C, Dritselis A, Kirkpatrick P. Tesamorelin. Nat Rev Drug Discov. 2011.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/19243281\/\"\u003eWang Y, Tomlinson B. Tesamorelin, a human growth hormone releasing factor analogue. Expert Opin Investig Drugs. 2009.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/17086939\/\"\u003eTomlinson B. Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor. Curr Opin Investig Drugs. 2006.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c!--$!--\u003e\u003ctemplate data-dgst=\"BAILOUT_TO_CLIENT_SIDE_RENDERING\"\u003e\u003c\/template\u003e\n \u003cdiv data-scroll-name=\"Certificate of Analysis (COA)\" class=\"\"\u003e\n  \u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\n    \u003ch2 class=\"mb-6 text-2xl font-semibold leading-[2.25rem] tracking-tight md:my-0\" id=\"certificates\"\u003e\n      Certificate of Analysis (COA)\n    \u003c\/h2\u003e\n  \u003c\/div\u003e\n\n  \u003cdiv class=\"flex w-full flex-row flex-wrap gap-x-0 gap-y-4 md:gap-x-8\"\u003e\n  \n    \u003cdiv class=\"w-1\/2 md:w-fit\"\u003e\n      \u003cdiv class=\"relative overflow-hidden rounded-none\"\u003e\n\t\t\u003ca href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0971\/5731\/6908\/files\/Tesamorelin.avif?v=1779880882\" target=\"_blank\"\u003e\n        \u003cimg alt=\"Certificate\" loading=\"lazy\" width=\"175\" height=\"227\" decoding=\"async\" data-nimg=\"1\" class=\"h-full w-full max-w-[150px] cursor-pointer rounded-none object-cover md:max-w-[175px]\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0971\/5731\/6908\/files\/Tesamorelin.avif?v=1779880882\" style=\"color: transparent;\"\u003e\n\t\t\u003c\/a\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/div\u003e\n\u003c\/div\u003e \n  \u003c!--\/$--\u003e\u003cdiv data-scroll-name=\"Resource\" class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" id=\"resources\"\u003eResource\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"w-full\"\u003e\u003cdiv class=\"text-base text-[#4B5563]\"\u003e\u003cspan\u003eAll products on this site are for research and development use only. Products are not for human consumption of any kind. The statements made on this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure, or prevent any disease. Power Peptides is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Power Peptides is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act. All products are sold for research, laboratory, or analytical purposes only, and are not for human consumption. Power Peptides Products are intended strictly for research purposes only. These products are not approved by the U.S. Food and Drug Administration (FDA) for human consumption or medical use. Under no circumstances should these peptides be used for any purpose other than research. By purchasing or using our peptides, you acknowledge and agree that you will use them solely in accordance with applicable laws and regulations and that you accept full responsibility for their use. Statements made on this website have not been evaluated by the USA Food and Drug Administration.\u003c\/span\u003e\u003c\/div\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"My Store","offers":[{"title":"5mg","offer_id":53240040259884,"sku":"PEP-VIL-TESA-5MG491023","price":18.99,"currency_code":"USD","in_stock":true},{"title":"10mg","offer_id":53240040292652,"sku":"PEP-VIL-TESA-10MG869111","price":25.99,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0971\/5731\/6908\/files\/tesamorelin-173584159219420250307-1741383450752.png?v=1779696806","url":"https:\/\/www.powerpieeptidesus.com\/products\/tesamorelin","provider":"Power Peptides","version":"1.0","type":"link"}